Eikon Therapeutics closes $148M financing to develop super-resolution microscopy
06 May 2021
California-based firm to integrate advanced optics, machine learning with biochemistry; its target application is drug discovery.
Eikon focuses on live-cell super-resolution microscopy for drug discovery.Eikon Therapeutics, a Hayward, California-based company focused on live-cell super-resolution microscopy and engineering for drug discovery, has this week announced that it has closed a $148 million Series A financing round.
The funding is led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. Eikon also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.
Eikon Therapeutics Closes $148M Financing Round, Names CEO | Business | May 2021 photonics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from photonics.com Daily Mail and Mail on Sunday newspapers.
Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm
Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.
Shares0
Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening , has emerged from stealth with $148 million in funding and a veteran Merck executive at the helm.
The Series A round of funding that Eikon announced Wednesday was led by The Column Group. Roger Perlmutter, the former president of Merck Research Laboratories is the Hayward, California-based startup’s CEO.
New era begins at Merck as pandemic cuts Q1 sales, profit - Business News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.